Shanghai Junshi Biosciences Co., Ltd.

10 月 16 日，默沙东宣布，PD-1 单抗 Keytruda 获 FDA 批准了第 6 项 NSCLC 适应症，用于治疗可切除（T≥4 cm 或 N+）NSCLC 患者，联合化疗作为新辅助治疗，然后继续作为单药作为术后辅助治疗。这项批准基于 KEYNOTE-671 研究的临床结果。今年 3 月，默沙东宣布该试验已达到 EFS 主要终点，并向 FDA 申报上市，PDUFA 决定日期在 10 月 16 日；6 月，基于第一次期中分析的 EFS 结果发表于 NEJM；10 月，默沙东又宣布达到了 OS 主要终点，将在本周即将举行的 ESMO 大会上公布结果。同日，K 药也在欧洲获批了辅助 NSCLC 适应症。截图来自：默沙东官网新闻页KEYNOTE-671 是一项随机、双盲全球多中心 3 期研究，首次启动于 2017 年 11 月（登记号：NCT03425643），共入组 786 例患者，1:1 随机分配到 K 药组和安慰剂组。中国内地也是其试验地点之一，在 CDE 登记于 2019 年 9 月，同年 12 月完成首例入组，共入组 118 人。默沙东 K 药的肺癌系列研究布局极广，在 ClinicalTrials.gov 上连同各种联合治疗方案，已经登记了超过 400 项，此前有 5 项肺癌适应症已经获批，涵盖二线、一线和辅助治疗。KEYNOTE-671 的成功和相应适应症的获批，将 K 药的覆盖范围再推进到了新辅助环境中。众所周知，肺癌是全球发病率和死亡率均居前列的致命癌种，2020 年 WHO 数据显示，全球有 220 万新发肺癌患者和 180 万例肺癌导致的死亡，而其中非小细胞肺癌占据了 81% 的比例。早期筛查无疑是延长肺癌患者生存时间的关键手段之一，对于早期肺癌患者的治疗，也仍存在着未满足的医疗需求。而对于早期肺癌患者的治疗，免疫疗法的成果正在批量涌现。今年 4 月，君实生物 PD-1 特瑞普利单抗基于 Neotorch 研究申报了 III 期 NSCLC 围手术期治疗适应症，成为首个递交该适应症上市申请的国产 PD-(L)1。本届 ESMO 中，不光 K 药要公布 KEYNOTE-671 的 OS 数据，BMS 也要公布 NSCLC 围手术期治疗的 CheckMate-77T 数据（LBA1），百济神州也将公布 RATIONALE-315 数据（LBA58）。封面来源：企业 Logo免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：加一PR 稿对接：微信 insightxb投稿：微信 insightxb；邮箱 insight@dxy.cn点击卡片进入 Insight 小程序国内审评进度、全球新药开发…随时随地查！多样化功能、可溯源数据……Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemotherapy — — Toripalimab demonstrated twelve-fold higher binding affinity to PD-1 compared to pembrolizumab — — In vitro studies show significantly higher activation of T cells compared to pembrolizumab in multiple assay systems — REDWOOD CITY, Calif., Oct. 14, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced a presentation of toripalimab data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023 at the Hynes Convention Center in Boston. PD-L1, a protein found on the surface of some cancer cells, suppresses T cell activation and inhibits the ability of the body’s immune system to kill cancer cells. Toripalimab is an anti-PD-1 monoclonal antibody that binds with high affinity to a unique site on PD-1, thereby blocking the interaction of PD-1 and PD-L1. Preclinical mechanistic data demonstrate statistically significantly higher activation of T cells and higher expression of key immune system activators with toripalimab compared to pembrolizumab, clinically a widely used anti-PD-1 monoclonal antibody for the treatment of cancer patients. These data may provide a mechanistic explanation for the improvements in overall survival irrespective of PD-L1 expression levels observed in clinical trials in multiple tumor types evaluating toripalimab in combination with chemotherapy. A biologics license application (BLA) for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) is currently under review by the U.S. Food and Drug Administration (FDA). “PD-1 inhibition has been a significant advancement in cancer treatment across tumor types but better treatments are needed to increase response rates and drive improved outcomes for patients. These data support toripalimab as a next-generation PD-1 inhibitor that, in combination with chemotherapy, may have greater antitumor activity in less inflamed tumors than more commonly used PD-1 inhibitors in certain cancers due to its unique binding properties,” said Theresa LaVallee, Ph.D., Coherus’ chief development officer. “We look forward to delivering this important new treatment option to patients, first in NPC, if approved, and continuing to evaluate its efficacy in combination with chemotherapy in multiple cancer types and in combination with novel I-O agents.” Poster presentation data are summarized as follows: Toripalimab in combination with chemotherapy significantly improved overall survival irrespective of PD-L1 status in post hoc analyses of 3 randomized controlled clinical trials, including in NPC, non-small cell lung cancer (NSCLC) and esophageal squamous-cell carcinoma (ESCC)Toripalimab exhibits a 12-fold higher binding affinity for PD-1 compared to pembrolizumab that is driven by a slow-off rateToripalimab is more potent than pembrolizumab in enhancing levels of Th1 cytokines and cytotoxicity in human peripheral blood mononuclear cells (PBMCs)In comparison to pembrolizumab, binding of toripalimab to PD-1 induced low levels of SHP1 and SHP2 recruitment, thereby minimizing a key process of T cell suppressionToripalimab induced and elevated IFN-y gene signature in NSCLC dissociated tumor cells with different kinetics and intensity compared to pembrolizumab Poster presentation details: Poster Number C069: Toripalimab, an anti-PD-1 antibody that demonstrates potent T cell activation and enhanced clinical efficacy irrespective of PD-L1 statusSession: Poster Session CDate and time: Saturday, October 14, 12:30 pm-4:00 pm EDTLocation: Level 2, Exhibit Hall D About toripalimabToripalimab is a next-generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD⁠-⁠1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types. The BLA for toripalimab in combination with chemotherapy as the first-line treatment for recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the FDA. In Europe, the marketing authorization applications (MAA) for toripalimab for the first-line treatment of NPC and esophageal squamous cell carcinoma (ESCC) are under review by the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The FDA granted Breakthrough Therapy designation for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC in 2021 as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC in 2020. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of ESCC, NPC, mucosal melanoma, soft tissue sarcoma, and small-cell lung cancer (SCLC). More than 40 company-sponsored toripalimab clinical studies covering over fifteen indications have been conducted globally by Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin. About Coherus’ Immuno-oncology PipelineCoherus is developing an innovative immuno-oncology pipeline that will be synergistic with its proven commercial capabilities in oncology. Through an in-licensing agreement with Junshi Biosciences, Coherus is developing toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of NPC is under review by the FDA. Toripalimab is approved in China for the treatment of melanoma, urothelial cancer, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and non-small cell lung cancer. Through its recent acquisition of Surface Oncology, Coherus’ immuno-oncology pipeline now includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug (formerly SRF388) is a novel anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 (formerly SRF114) is a highly selective, competitively positioned anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors. There are also two out-licensed partnership programs to advance its next-generation cancer therapies. Coherus’ earlier-stage immuno-oncology pipeline targets immune-suppressive mechanisms in the tumor microenvironment, including CHS-006, a TIGIT-targeted antibody, being evaluated in a Phase 1/2 clinical trial in combination with toripalimab in patients with advanced solid tumors, and CHS-1000, a preclinical program targeting the novel pathway ILT4. About Coherus BioSciencesCoherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma is currently under review by the FDA. Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira®. Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ ability to build its immuno-oncology franchise to achieve a leading market position; Coherus’ ability to generate cash and net sales; Coherus’ investment plans; Coherus’ ability to find synergies between its I-O pipeline and its commercial operations; expectations about the efficacy and safety profile of any product candidate; and Coherus’ ability to launch or achieve FDA approvals for any product candidate in the future. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to integration of Surface’s programs and operations; risks related to realizing the anticipated benefits of the acquisition of Surface; risks related to Coherus’ existing and potential collaboration partners; risks of Coherus’ competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus’ business and the timing of Coherus’ regulatory filings; the risk of FDA review issues; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ products and product candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 filed with the Securities and Exchange Commission on August 2, 2023, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. UDENYCA®, CIMERLI® and YUSIMRY™, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners. Coherus Contact Information:For Investors & MediaJodi Sievers, VP, Corporate Communicationsir@coherus.com

生物行业寒冬愈发凛然，可物极必反，连续不断的爆雷、出清，剔除了那些影响行业可持续发展的“泡沫”后，以头部药企为冲锋队、以新一代创新药企为后备军的梯队格局，渐渐显露了出来。三年前，E药经理人携手全球领先的专业信息服务提供商科睿唯安联合，在“中国医药创新企业100强”榜单（以下简称“创新100”）的基础上，隆重推出了子榜单——“中国医药创新种子企业100强”（以下简称“种子100”）。两者交相辉映，更为全面真实地反映中国医药创新的现状和未来。“种子100强”延续了“创新100强”的基本研究框架，是以创新根基、创新过程、创新成果为主要评价体系，基于科睿唯安Derwent Innovation专利数据及Cortellis™竞争情报和临床试验数据，通过对授权专利数量和专利施引总量、在研临床试验数量、获批与上市新药数量指标进行数据化处理，从5000多家中国药企中遴选而来。它们的共同特点是：大多成立时间不长，以Biotech公司为主，拥有独特的创新产品（技术），尚未登陆资本市场，不为大众所熟知，但俨然已经成为中国医药创新强大的后备军。每一年，这份榜单都有所变化。而今年，能在寒冬存续下去、并保留创新火种的企业们，不光都拥有一份完善的价值观和方法论，更昭示着中国医药产业的新生。以下为“中国医药创新种子企业100强”榜单：通过对本届“种子100”的深入分析，我们有三大发现：一，中国医药创新“年轻化”趋势进一步深化，“18后”开始崭露头角；二，传统企业不甘人后，持续创新迭代；三，肿瘤领域霸主地位依旧稳固，各种疗法“百花齐放”。医药创新呈现显著“年轻化”趋势“18后”开始崭露头角过去10年，中国新成立了数千家生物科技公司，其中，以百济神州、信达生物、再鼎医药等为代表的一批新贵率先尝到创新药的红利。强势挑战着中国医药行业的“旧秩序”。随后，政策和资本都给创新药行业释放出了大量利好，让越来越多创新药企迅猛跨入到了“种子100”行列。从榜单来看，若以2018年4月香港联合交易所在主板上市规则中新增第18A章《生物科技公司》，允许未有收入、未有利润的生物科技公司提交上市申请为时间节点来划分，本届“种子100”中有近20%的创新药企成立于2018年之后，当然，不能说它们的成立就是受了18A红利的刺激，但中国医药创新呈现出了越发显著的“年轻化”趋势，也是板上钉钉的事实。这些“新生代”们各自有着不同的专长，要么有独家技术，要么有创新的商业模式，要么有强大的业务拓展能力，能够迅速为自身的研发管线找到BD出口。以成立于2019年的礼新医药为例，其在license-out方面取得了连续进展。2022年，与美国肿瘤精准疗法公司Turning Point针对Claudin 18.2创新抗体偶联药物（ADC）LM-302达成海外独家授权合作；今年5月，又宣布将旗下已获批进入临床阶段的ADC药物GPRC5D的研究、开发和商业化的独家全球许可授予阿斯利康。成立于2018年，聚焦于癌症、病毒感染和自身免疫疾病的小分子新药研发的征祥医药在寒冬中则选择了拥抱国内老牌传统药企。9月18日，济川药业宣布以自有资金6000万元认购征祥医药股份，交易完成后，济川药业持有征祥医药3.4052%的股份。这是继今年8月5日双方达成一次独家BD合作协议后的进一步深度合作。许多“新生代”取得了远超过很多老牌公司的高估值，它们的优势，在于拥有众多高质量创新专利；而劣势是，大部分管线依然处于早期研发阶段，涉及的细分技术方向都相对前沿，缺乏商业化能力，寒冬中需要进一步降本增效，并寻求资本的支持。传统企业持续创新迭代人们总习惯于把创新当作年轻人的“专属”，可事实上，传统企业也在不断蜕变，并拿出了越来越多的创新成果。原因不难理解，传统企业们本就拥有更强大的商业化团队、更完善的政产学研医配合思路、更深厚的资金储备，需要改变的往往只是管理理念和研发重点。榜单上，若以2009年“新医改”推行来划分，本届“种子100”中有高达30%以上的企业成立于2009年之前，其中有些甚至还拥有颇为悠久的历史，例如资格最“老”的苏中药业始建于1972年，致力于中药现代化的实践，同时也在心血管、肿瘤等治疗领域以临床需求为导向，拓展具有特色的仿创结合的化学药物的研究与开发，今年以35个IP1授权专利数量、66个IP2 DPCI施引总数入选榜单。成立于1988年的成都地奥集团是一家集天然药物、合成药物、基因工程药物为一体的大型骨干制药企业，以“第一家中成药进军海外的破冰者”知名。今年，其以6个活跃药物、37个IP1授权专利数量、35个IP2 DPCI施引总数入选榜单。一些企业的前身是国家科研院所。比如云克药业的前身就是中国核动力研究设计院成都同位素应用研究所，2001年改制成立，目前在国内核素治疗药品供应上处于领先地位；天津药物研究院始建于1959年，是原国家医药管理局直属的全国综合性医药科研单位之一，2002年改制成立，就在前不久，其自主研发的1类创新药泰普格雷片脑卒中适应症获批了II期临床。还有远大生命科学集团，其重要组成部分四川远大蜀阳药业有限责任公司的前身是成都蜀阳制药厂，成立于1985年，更早时候是1969年创办的成都军区后勤部血浆所，1998年移交成都市政府，2001年由中国远大集团公司全资收购。如今的远大生命科学集团在血液制品的基础上延伸开去做创新药研发，取得了一系列成果。这些企业能够穿越数个周期，持续创新迭代，不光是因为“内功”深厚，敢于破旧迎新，也凸显出了宏观环境的残酷：2015年药物创新制度改革之后成立的药企，许多难免被资本所“催熟”，还来不及建立起完整的商业闭环，寒冬里被传统药企迎头赶上亦属情理之中。肿瘤领域霸主地位依旧稳固各种疗法“百花齐放”前几年，最受投资人青睐的新技术是细胞基因疗法（CGT疗法）。相关数据显示，自2015年开始，中国CGT疗法的临床试验数量增长快速，2015-2020年间，累计开展了约250项CGT临床试验，数量仅次于美国，年复合增长率超过60%，位列全球第一。2021年，两款CAR-T疗法在中国相继获批上市，标志着中国的血液瘤患者正式迈入细胞治疗时代，而基因疗法在国内进度相对较为缓慢。2021年，“种子100”榜单发布的第一年，细胞基因疗法占得了新技术的绝对主流，当年相关企业数量超过了20家。然而CGT赛道不光竞争极为激烈，成本还一直居高不下，并且实现突破的疾病领域相对较窄，可及性等问题严重限制了市场增长。目前的中国市场上，仅有的三款CAR-T细胞疗法价格均超过百万元，是普通人难以负担之重。各种障碍下，今年以来，“种子100”榜单里从事细胞基因疗法的创新企业数量减少到了20家以下。不过剩下的CGT企业经过大浪淘沙，几乎都掌握了独家技术和产品。譬如开发出了伊基奥仑赛注射液的驯鹿生物，拥有多项技术专利的北恒生物，于今年年中完成了新一轮融资的艺妙神州等。榜单中其它新技术则集中在双特异性抗体、ADC、肿瘤疫苗、溶瘤病毒、AI+新药研发领域。而从疾病治疗领域上看，肿瘤仍占绝对主流，占比超过50%。值得关注的是，“种子100”中也有不少药企不再选择扎堆于肿瘤，而是选择开辟其他蓝海赛道，以期形成差异化竞争优势。例如2018年成立的安济药业主要聚焦代谢类疾病领域，除血脂异常外，还在疼痛、心脑血管等多个慢性疾病领域均有布局；2019年成立的箕星药业则专攻心血管和眼科疾病领域。“种子100强”企业作为代表中国医药创新潜力的第一阵营，是中国医药产业转型升级，打造产业竞争力的重要后备力量。如想获取更多“种子100”及“创新100”详情，请关注2023年11月1日～3日在杭州举办的2023’中国医药企业家科学家投资家大会。预判趋势，找准穿越周期的正确姿势供给端、支付端、资本端、政策端、市场端，医药产业每一环在资本寒冬催动的新周期里，都面临着价值重塑。我们需要急迫地寻找每项的答案——医药产业下一个5年长什么样？你的公司5年后在产业里扮演什么角色？在暧昧不明的新周期里，药企如何夯实内功，降本增效，让公司基业长青？Pharma、Biotech、资本方在穿越周期的大命题下如何互相辅佐、砥砺前行、共创未来？中国创新药海外市场拓展多年，成绩少折戟多的原因到底在哪儿？破局的关键是什么？源头创新和商业实现间的平衡如何达成？炙热到滋滋冒泡的各大细分技术赛道，是否孕育着中国新药在全球市场奋起一搏的火苗和希望？中国医药企业家科学家投资家大会作为行业发展共识与洞见的策源地，在这里500+企业家，100+科学家，200+投资家莅临思辨，看清未来趋势、达成头部共识、夯实创新业务底色。图丨2019年启思会精彩瞬间五大行业风向标报告——产业风向标，明确医药产业高质量发展内涵；政策风向标，清晰创新生态建设版图；技术风向标，看准未来生物技术风向；创新风向标，锚定中国创新全球定位；投资风向标，量度资本市场冷暖。五大战略痛点思辨——从公司内功和产业生态出发，探寻创新的可持续性；License out与全球新，组团出海与一带一路，探寻中国特色的医药国际化之路；Biotech与Pharma共生，BD与商业化协同，探寻创新的逻辑闭环；产学研的新格局与投资链的进化，临床需求与关键生态，探寻资本驱动创新；新技术与供应链，新合作与产业链条，探寻医药企业降本增效。八大技术赛道最新成果分享——基因与细胞治疗技术；核酸类药物技术；抗体偶联类药物技术；创新抗体技术；高端制剂；体外诊断；BI+IT；……促进交易合作，助力价值变现合作是价值释放的唯一利器。医药创新资本寒冬下，行业已经形成Bigpharma、Biopharma和Biotech三者共存局面。穿越周期，共克时艰需要纵向、横向链接更精准、更务实、更有效率。E 药经理人深挖产业供需，凝聚医药供应链上、中、下游头部企业资源，倾力搭建“Link Value 价值领航”对接平台，助力创新生物药企高质量发展，促进资本、 Pharma公司和创新之间的合作、交易、融合，助力价值变现。第15届中国医药企业家科学家投资家大会将成为推动资本、大药企、Biotech交易融合，价值“光合作用”发酵最系统、精准的资源链接平台。四种方式六大领域全方位展示——论坛、路演、线下互动、一对一精准对接；设置1000平米展区，聚焦CGT赛道可持续发展；优选肿瘤、皮肤自免、神经、心脑血管、内分泌等疾病领域项目进展分享。助力五大上下游供应链全价值服务触达——实验室仪器、试剂、耗材，最新技术展示；医药生产设备，系统服务方案对接；CRO、CDMO等生命科学服务支持上下游企业最新、最全价值服务展示；中国特色产业园区与医药生态全链条头部、新锐企业的价值互选；中国医药创新企业、最具竞争力医药上市公司、最具投资价值医药上市公司的创新品牌升级。图丨2020年启思会精彩瞬间十大细分领域榜单，清晰创新生态建设版图从这里看清趋势，从这里瞄准世界。这是中国医药企业家科学家投资家大会的使命，也是中国头部企业和头部企业家的担当。作为医药行业各领域头部企业集结地，第15届中国医药企业家科学家投资家大会让发布十大细分领域榜单，发掘公司价值，提升品牌认知，清晰创新生态建设版图。十大细分领域榜单——中国医药上市公司竞争力、创新与投资价值榜单；中国医药创新企业100强及中国医药创新种子企业100强榜单；中国生命科学服务企业品牌100强榜单；中国医药上市公司ESG竞争力系列评选榜单；中医药药传承与创新案例50发布与案例分享；中国医药创新项目100佳榜单；医药数字化营销优秀服务商评选榜单；2023年度中国券商十大医药技术研报分享。特色领域、领军人物齐聚，赋能战略提升业绩中医药CEO大会，中药头部企业当家人集结，诊断中药传承痛点，共谋中药创新新路径；领军人才发展论坛，从战略到战术，于挑战里寻新机；医药创新高端沙龙，可持续的高端洞察和经验交流互鉴，倡导卓越创新理念，汇集创新思想与共识；医药市场百人研究会营销创新论坛，降本增效创价值，高效赋能可持续。回复“新生”了解电子期刊详情登记邮箱信息订阅E药经理人信息服务扫描二维码精彩推荐CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化 ｜ 猎药人系列专题启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖 ｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 |  荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药 ｜再鼎医药｜亚虹医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元